Latest Genmab News & Updates

See the latest news and media coverage for Genmab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Genmab

Therapeutic antibody developer

genmab.com

Headquarters: 2500 Valby, Denmark
Company type: Public company
Number of employees: 3,000–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Genmab

In short: Genmab raised its 2026 financial guidance after strong H1 results and secured European approval for an epcoritamab combination therapy.

Company announcements

September 1 Genmab

Genmab appoints new CEO for Italy and Spain

Fernández-Baca brings more than two decades in biotechnology to drive commercial growth and the company's oncology mission in these markets.

August 6 Genmab

Genmab reports strong first half 2026 financial results

Revenue reached $2,051 million driven by higher royalties and product sales, while management raised full-year forecasts amid positive clinical trial data.

July 23 Genmab

Genmab and AbbVie clarify trial missed OS endpoint

The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab in relapsed/refractory DLBCL; overall survival, the US primary endpoint, was not met.

July 15 Genmab

Genmab reports Q2 2026 DARZALEX net sales of USD 4,207 million

Sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. Genmab receives royalties from Johnson & Johnson.

Media coverage

September 8 Ad hoc news

Genmab stock heads into the open after new share issue news

At the close on September 8, 2026, Genmab stock reflected investor attention on a newly announced employee warrant share issuance; trading today comes as the...

September 7 Ad hoc news

Genmab shares rise on strong Q2 figures and raised forecast

Genmab shares benefit from solid Q2 2026 figures and an upgraded annual forecast. For investors, the combination of double-digit revenue growth, improved profitability, and progress with antibody Epcoritamab...

September 4 Finans

Genmab receives a visit from AbbVie on its home ground

On Thursday, the American pharmaceutical company AbbVie presented promising results from a phase 3 study with the drug candidate etentamig for the treatment of bone marrow cancer.

August 27 The Globe and Mail

Genmab's Petosemtamab Trial Emerges as a New Catalyst in Colorectal Cancer

Genmab (OTC: GMAB) is advancing a Phase 3 study called LiGeR-CRC2 in colorectal cancer that has come back, cannot be removed by surgery, or has...

Never miss news about Genmab

Track Genmab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Genmab competitors & trending companies

Browse news for competitors to Genmab and other trending companies.